Celsius Holdings (CELH): Priced for the Bear Case — Oct 2026 Valuation

by psind707

Verdict: UNDERVALUED. Probability-weighted fair value $41.63 vs $26.92 (+55%).

Valuation date: October 8, 2026. Price as of October 7 close. Methodology: Damodaran three-stage FCFF DCF, four probability-weighted scenarios, SBC deducted as a cash cost, PepsiCo preferred stock modeled as senior claims. Peer relative valuation as cross-check. Reverse DCF as sanity check.

Summary

Celsius has fallen 58% from its October 2025 high of $64.86 after the core CELSIUS brand went from +7.5% growth in FY2025 to a decline of 11.7% in Q2 2026. The market has concluded that the brand is broken and the company is now a low-growth staples name at a staples multiple.

My reading is different. The US energy category is growing 7% in dollars; the zero-sugar sub-segment is growing faster; Alani Nu grew retail sales 56% and is now a $1.5B-plus brand on a run-rate basis; and the CELSIUS brand decline is at least partly self-inflicted (a 7% cut in distribution points plus a deliberate innovation pause during two acquisition integrations). Management's own words on the Q2 call: "We went too deep on the CELSIUS rationalization."

At $26.92 the stock discounts either a 3% annual revenue decline through 2030 or a permanent 17% EBIT margin. Neither matches a portfolio that holds 20% of a growing category and earns 24% adjusted EBITDA margins today.

The business

Three brands, all in US ready-to-drink energy, all distributed by PepsiCo in the US and Canada:

PepsiCo owns approximately 11% of CELH on an as-converted basis through two series of 5% convertible preferred stock and holds two board seats.

Why the stock collapsed

1. Core brand reversal. CELSIUS brand revenue: +7.5% FY2025, +6% Q1 2026, −11.7% Q2 2026. Management cut approximately 7% of distribution points in a SKU rationalization and paused new flavor launches while integrating Alani Nu and Rockstar. Energy drinks depend on innovation cadence and shelf presence; pulling both at once handed space to competitors.
2. Cannibalization fear. The bear reading is that Alani Nu's growth comes partly from CELSIUS's own zero-sugar, health-positioned consumer.
3. Gross margin down 340bp to 48.1% from 51.5%: heavier promotional spend, aluminum inflation, and Alani Nu's move into Pepsi's DSD system, which carries higher trade allowances that net against revenue.
4. Three consecutive earnings misses. Q2 revenue $818M vs $872M consensus; adjusted EPS $0.36 vs $0.42; GAAP net income −45%. Stock fell 18% on the day.
5. Governance noise. Deutsche Bank downgraded to Hold in August citing no core-brand recovery before 2027. Rockstar founder Russ Savage took a 4.7% stake and publicly called for the CEO's removal. The COO departed August 10.
6. Multiple reset. From approximately 5x sales and 35x forward earnings at the peak to 2.3x sales and 20x forward earnings today.

The category is not the problem

CELSIUS brand lost approximately 9 points of relative growth against the category. That is a share problem, not a demand problem. The shrinking part of the market is the legacy sugared brands (Rockstar, NOS, Bang, Reign).

Verified inputs

The gap between GAAP and adjusted operating income is dominated by one-time distributor termination fees from moving Alani Nu into the Pepsi system. I use adjusted EBIT in the model but deduct SBC in full as a cash cost.

Preferred stock treatment

Both PepsiCo preferreds rank ahead of common. Series B converts at $51.75 and is treated as a $585M debt-like claim in every scenario. Series A converts at $25.23: in scenarios where fair value per share exceeds $25.23 it is treated as converted into 21.8M common shares; in the bear case, where value falls below the conversion price, it is treated as a $550M senior claim. Ignoring these two instruments would overstate common equity value by roughly $4-5 per share.

Cost of capital

Bottom-up build. Market cap is below $15B, so no raw regression beta.

Scenarios

Ten-year explicit forecast (FY2026-FY2035), 3% terminal growth, 20% terminal ROIC, 25% tax rate, sales-to-capital 2.5x, SBC scaled with revenue and deducted from FCFF.

Base case detail: revenue $3.46B in 2027, $4.35B in 2030, $5.42B in 2035. Terminal value is 66% of enterprise value. Base-case enterprise value $11.6B, equity $11.0B after debt, cash, and Series B.

The narrative-shift scenario is included because Alani Nu's tracked-channel retail growth exceeded 50%, which under my framework requires a fourth scenario at 10-15% weight.

Base case sensitivity (fair value per share)

Even at 9% WACC and 2% terminal growth the base case clears the current price.

Reverse DCF: what $26.92 assumes

Holding base-case margins (21.5% rising to 23.5%), the price implies a 2027-2030 revenue CAGR of −3.1%.

Holding the base-case growth path, the price implies a permanent adjusted EBIT margin of 16.8%, versus 21-22% today and 28% at the Q2 2025 peak.

Both conditions describe a company whose H1 2026 problems are structural. The evidence (growing category, Alani Nu momentum, dollars per distribution point up 16% quarter over quarter after the SKU cuts) points to self-inflicted and recoverable.

Peer relative valuation

CELH trades at PepsiCo's multiple with Monster's growth forecast. At half of Monster's EV/EBITDA (13.9x) on TTM adjusted EBITDA, common equity is approximately $34 per share after both preferreds. At KDP's 15.4x, approximately $38. The discount to Monster is justified by execution risk and the preferred overhang, not by growth or margin structure.

Consistency gate: DCF and growth-adjusted comps fall within 2x of each other, so the valuation is publishable under my framework.

Pricing: what moves the stock from here

Value and price are different questions. The DCF says UNDERVALUED; these are the factors that determine whether and when the gap closes.

• Catalyst: Q3 2026 earnings, November 5. Management guided Q3 CELSIUS brand to look "very similar" to Q2, with a return to growth in Q4. A print in line with that guide is already priced. The downside risk is another gross margin miss on aluminum.
• Insider buying. CEO John Fieldly bought 18,000 shares at $27.44 on September 9. Four current insiders bought approximately $1.94M in total between $27.44 and $28.00 after the Q2 miss. This is the first open-market CEO purchase I can find in the filing history; prior activity was a $7.3M sale at $51.18. The block sales at $46.25 before Q2 were 10b5-1 distributions by former insiders.
• Activist. Russ Savage at 4.7%, below the 13D threshold. PepsiCo's 11% stake and board seats make a hostile CEO change unlikely, but the campaign puts a floor under the turnaround narrative.
• Buyback. $124.5M repurchased in H1 2026 at an average price around $30. Management has room to accelerate at these levels.
• Short interest at 14% of float adds fuel to any positive surprise.

Thesis-break triggers

• CELSIUS brand tracked retail sales down more than 5% in Q4 2026 data
• Gross margin below 47% for two consecutive quarters
• Alani Nu tracked retail growth below 25%
• Any amendment to the PepsiCo distribution agreement

Position framing

For readers who use options: longer-dated calls (January 2028, $30-35 strikes) fit a fair-value-to-price ratio of 1.55x. Avoid anything expiring around the November 5 print. Strike selection should be checked against current implied volatility; I have not pulled the chain for this note.

Documented facts vs my interpretation

Documented: all financial figures above are from the Q2 2026 Form 8-K exhibit 99.1, the FY2025 Form 8-K, the FY2025 Form 10-K, Monster's Q2 2026 Form 8-K, and stockanalysis.com (S&P Global Market Intelligence) as of October 7, 2026. The CEO quote is from the Q2 2026 earnings call. Insider transactions are from Form 4 filings as summarized by TIKR; I have not independently pulled each Form 4.

My interpretation: that the CELSIUS brand decline is mostly self-inflicted and recoverable; the scenario weights; the margin recovery path; the 7.89% WACC; the treatment of Series A as converted in the base and bull cases.

Post-mortem cadence

This valuation will be re-run after the Q3 2026 (November 5) and Q4 2026 (February 2027) results. A price divergence above 50% from fair value in either direction triggers a versioned V2 with attribution between fundamentals and multiple.

This is not investment advice. I hold no position in CELH at the time of publication.